Trial Profile

An Open-Label, Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LOXO 435 (Primary) ; Pembrolizumab
Indications Carcinoma; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

11 Oct 2023 Planned number of patients changed from 140 to 180.
19 Apr 2023 Trial design presented at the 114th Annual Meeting of the American Association for Cancer Research
20 Jan 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com